Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

By Padmanee Sharma, M. Retz, A. Siefker-Radtke, A. Baron, A. Necchi, J. Bedke, E. Plimack, D. Vaena, M. Grimm, S. Bracarda and 9 more. The Lancet Oncology, 2017

1,512 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/4de2546ac03fa36d49fd75c6a8686a4aa093384b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. B. V. van Rhijn
2. William Y. Kim

Citations in the corpus

• Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “This formed the basis of its accelerated approval on 2 February 2017 for surgically unresectable or metastatic urothelial cancer [43] (Category 2A).”
• European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. (2020, neutral): “Immunotherapy combinations may be effective in the second-line setting, but data are currently limited [205 – 208].”
• Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. (2017, methodology): “However, in the recently published CheckMate 275 trial, patients with basal tumors appeared to benefit from nivolumab, another checkpoint inhibitor [19].”